Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-01-06FDA Approved: HUMALOG MIX50/50 KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for HUMALOG MIX50/50 KWIKPEN (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2017-01-06FDA Approved: HUMALOG KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Humalog KwikPen (insulin lispro) by Eli Lilly.
-
FDA approval · 2016-12-29FDA Approved: GLIPIZIDE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings, Inc.'s original application for a generic version of glipizide to treat type 2 diabetes mellitus.
-
FDA approval · 2016-12-23FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approves a supplemental application for Tradjenta (linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc., enabling an updated…
-
FDA approval · 2016-12-23FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO (linagliptin and metformin hydrochloride) from Boehringer Ingelheim Pharmaceutica…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-12-23FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA approval · 2016-12-23FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY, the fixed-dose combination of empagliflozin and metformin hydrochloride, submitted by …
-
FDA approval · 2016-12-23FDA Approved: JENTADUETO XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for JENTADUETO XR (linagliptin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharma…
-
FDA approval · 2016-12-23FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Synjardy XR, a fixed-dose combination of empagliflozin and metformin hydrochloride, from Boe…
-
FDA approval · 2016-12-16FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for TRESIBA (insulin degludec) submitted by Novo Nordisk.
-
FDA approval · 2016-12-14FDA Approved: PIOGLITAZONE AND METFORMIN HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Pioglitazone and Metformin Hydrochloride fixed-dose combination from Macleods Pharmaceuticals Li…
-
FDA approval · 2016-12-12FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for alogliptin, submitted by Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2016-12-12FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for a fixed-dose combination of pioglitazone and glimepiride (Prasco Laboratories). The indicati…
-
FDA approval · 2016-12-12FDA Approved: ACTOPLUS MET — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ACTOPLUS MET (pioglitazone and metformin hydrochloride) from Takeda Pharmaceuticals America, Inc…
-
FDA approval · 2016-12-12FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for KAZANO (alogliptin and metformin hydrochloride) filed by Takeda Pharmaceuticals America, Inc., i…
-
FDA approval · 2016-12-12FDA Approved: ACTOS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ACTOS (pioglitazone) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2016-12-12FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for the fixed-dose combination of alogliptin benzoate and pioglitazone from Padagis Israel Pharm…
-
FDA approval · 2016-12-09FDA Approved: SYNJARDY XR — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved SYNJARDY XR as an original application for a fixed-dose combination of empagliflozin and metformin hydrochloride (XR formul…
-
FDA approval · 2016-12-07FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
The FDA approved Metformin Hydrochloride from Macleods Pharmaceuticals Limited under an original ANDA, establishing a generic version of met…
-
FDA approval · 2016-11-23FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Toujeo (insulin glargine) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2016-11-21FDA Approved: SOLIQUA 100/33 — Original Application (Sanofi-Aventis U.S. LLC)
FDA approved SOLIQUA 100/33, a fixed-dose combination of insulin glargine and lixisenatide, marking the original approval of this product. I…
-
FDA approval · 2016-11-21FDA Approved: XULTOPHY 100/3.6 — Original Application (Novo Nordisk)
FDA approved XULTOPHY 100/3.6, a fixed-ratio combination of insulin degludec and liraglutide, under an original application. It is indicated…
-
FDA approval · 2016-10-07FDA Approved: NOVOLOG — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for NovoLog (insulin aspart) by Novo Nordisk.
-
FDA approval · 2016-09-20FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for liraglutide by Teva Pharmaceuticals USA, Inc., indicating an approved modification to the produc…
-
FDA approval · 2016-09-20FDA Approved: INVOKAMET XR — Original Application (Janssen Pharmaceuticals, Inc.)
FDA approved INVOKAMET XR (canagliflozin and metformin hydrochloride) through an Original Application. It is indicated for the treatment of …